2.1
Asfotase alfa (Strensiq, Alexion Pharma UK) is indicated for 'long-term enzyme replacement therapy in patients with paediatric‑onset hypophosphatasia to treat the bone manifestations of the disease'.
2 Information about asfotase alfa
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for asfotase alfa.
Price
2.3
The list prices for asfotase alfa are:
-
£12,700.80 per 12-injection vial, which contains 18 mg/0.45 ml of asfotase alfa (excluding VAT; BNF online, accessed December 2022)
-
£19,756.80 per 12-injection vial, which contains 28 mg/0.7 ml of asfotase alfa (excluding VAT; BNF online, accessed December 2022)
-
£28,224.00 per 12-injection vial, which contains 40 mg/1 ml of asfotase alfa (excluding VAT; BNF online, accessed December 2022)
-
£56,448.00 per 12-injection vial, which contains 80 mg/0.8 ml of asfotase alfa (excluding VAT; BNF online, accessed December 2022).
The company has a commercial arrangement. This makes asfotase alfa available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.